ClinicalTrials.gg
CompletedNCT02332707Updated Jul 23, 2019Results posted

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)

A Phase 2 interventional study of Grazoprevir and Uprifosbuvir in Hepatitis C, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-23.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
443
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing grazoprevir in Hepatitis C — none open to participants now, none under way, none of them phase 3. grazoprevir · Hepatitis C.

Enrollment
2nd of 18
443 · median 119
Started
2015
the only one that year
Phase 2
6 of 18
none open now
Registered
12th of 18
by date
Lead sponsor
13 of 18
Merck Sharp & Dohme LLC

Among the 18 studies testing grazoprevir in Hepatitis C, this one is the 2nd largest by enrollment, is the only one that started in 2015, is one of 6 in phase 2, and was the 12th registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

None of the 18 studies testing grazoprevir in Hepatitis C is open now. The open studies under Hepatitis C, anywhere →

Where they have run

About grazoprevir

grazoprevir: first FDA approval 2016 (ZEPATIER), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing grazoprevir in Hepatitis C as a file.
02

Study summary

This is a randomized, three-part, open-label trial of grazoprevir (GZR; MK-5172) (100 mg) and uprifosbuvir (UPR; MK-3682) (300 mg or 450 mg), with either elbasvir (EBR; MK-8742) (50 mg) or ruzasvir (RZR; MK-8408) (60 mg), and with or without ribavirin (RBV), in treatment-naïve (TN) cirrhotic (C) or non-cirrhotic (NC) hepatitis C virus (HCV) participants with chronic HCV genotype (GT) 1 or GT2 infection. Part A will consist of 8 arms to evaluate the safety of dose combinations. In Part B, participants will take 2 UPR+GZR+RZR fixed dose combination (FDC) tablets once daily (q.d.) by mouth, with or without twice-daily (b.i.d.) RBV (200 mg capsules; weight-based dosing). Participants who relapse following completion of therapy in Part A will be offered the option of retreatment with 16 weeks of UPR+GZR+RZR with RBV in Part C (data obtained from Part C will not be used in the analysis of outcome measures).

Read the detailed description

In Part A, study therapy will be administered as separate products, each taken q.d. by mouth. In Part B and Part C, participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg q.d. by mouth.

03

Conditions studied

  • Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Parts A and B:

  • Previously untreated chronic GT1 or GT2 with no evidence of non-typeable or mixed genotype infection
  • Has HCV ribonucleic acid (RNA) >= 10,000 IU/mL in peripheral blood at the time of screening
  • Is NC (Part A and B)
  • Is HCV treatment naïve (defined as no prior exposure to any interferon, ribavirin, or other approved or experimental HCV-specific direct-acting antiviral agent
  • Is of non- or agrees to avoid becoming pregnant or impregnating a partner beginning at least 2 weeks prior to administration of the initial dose of study drug and either for 14 days after the last dose of study drug if not taking RBV or for 6 months after the last dose of study drug if taking RBV (or longer if dictated by local regulations). If not abstinent from heterosexual activity, participants in Part A must use 2 acceptable forms of barrier whereas participants in Part B must use 2 acceptable forms of contraception which may include oral contraceptives

Part B only:

  • Has cirrhosis of the liver
  • If coinfected with (HIV) is not currently on antiretroviral therapy (ART) and has no plans to initiate ART treatment while participating in this study OR has well controlled HIV on ART (the ART regimen must contain only the following antiretroviral medications: tenofovir, abacavir, lamivudine, emtricitabine, raltegravir, dolutegravir, and rilpivirine with no dose modifications or changes in drugs in the 4 weeks prior to study entry [Day 1])
  • Has at least one viable ART regimen alternative beyond their current regimen in the event of HIV virologic failure and the development of antiretroviral drug resistance

Exclusion criteria

Exclusion Criteria:

Parts A, B, and C (unless noted otherwise):

  • Has evidence of decompensated liver disease manifested by the presence of or history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other signs or symptoms of advanced liver disease
  • For cirrhotics (Part B only), participants who are Class B or C or who have a Pugh-Turcotte (CPT) score >5
  • Is coinfected with virus
  • Is coinfected with (Part A only)
  • If coinfected with HIV (Part B only), has a history of opportunistic infection in the preceding 6 months prior to screening
  • Has a history of \<=5 years prior to signing except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer or carcinoma in situ; or is under evaluation for other active or suspected malignancy
  • Has cirrhosis and has had liver imaging within 6 months of Day 1 showing evidence of hepatocellular carcinoma (HCC) or is under evaluation for HCC
  • Has clinically-relevant drug or alcohol abuse within 12 months of screening
  • Pregnant or breast-feeding, or expecting to conceive or donate eggs from at least 2 weeks prior to Day 1 and 90 days after the last dose of study medication, or longer if dictated by local regulations
  • Has any of the following conditions:
  • organ transplants (including hematopoietic stem cell transplants) other than cornea and hair
  • poor venous access that precludes routine peripheral blood sampling required for this trial
  • has a history of gastric surgery (e.g., stapling, bypass) or history of malabsorption disorders (e.g., celiac sprue disease)
  • current or history of any cardiac abnormalities/dysfunction, including but not limited to: angina, congestive heart failure, myocardial infarction, pulmonary hypertension, complex congenital heart disease, cardiomyopathy, significant arrhythmia, uncontrolled hypertension, a history of use of antianginal or anti-arrhythmic agents for cardiac conditions, prolonged (ECG) (>470 ms for males or >480 ms for females by the Fridericia formula) at the screening visit, personal or family history of Torsade de pointes
  • chronic pulmonary disease, including but not limited to: clinically significant , interstitial lung disease, pulmonary fibrosis, sarcoidosis
  • central nervous system (CNS) trauma requiring intubation, intracranial pressure monitoring, brain meningeal or skull surgery, or resulting in seizure, coma, permanent neurologic deficits, abnormal brain imaging, or cerebral spinal fluid (CSF) leak. Prior brain hemorrhage and/or intracranial aneurysms (whether adequately repaired or not)
  • a current, or history of, seizure disorder unless seizure was >10 years ago, a single isolated event, no history of or current use of anti-seizure medications prescribed, and a normal neurological examination is documented in trial files within 6 months of Day 1
  • a history of stroke or
  • a history of a medical/surgical condition that resulted in hospitalization within the 3 months prior to enrollment, other than for minor elective procedures
  • a medical/surgical conditions that may result in a need for hospitalization during the period of the study
  • any medical condition requiring, or likely to require, chronic systemic administration of , tumor necrosis factor (TNF) antagonists, or other drugs during the course of the trial
  • has any condition, prestudy laboratory or ECG abnormality or history of any illness, which, in the opinion of the investigator, might confound the results of the study or pose additional risk in administering the study drugs to the subject
  • experiences a life-threatening serious adverse event (SAE) during the screening period
  • evidence of history of chronic hepatitis not caused by , including but not limited to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, hemochromatosis, Wilson's disease, α1-antitrypsin deficiency, alcoholic liver disease, and hepatitis
  • hemoglobinopathy, including, but not limited to, thalassemia major (Parts B and C only) Parts B and C only: is a male whose female partner(s) is/are pregnant
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
443 participants (actual)

Study arms

  • Experimental
    A1: GT1 NC GZR+UPR+EBR (8 weeks)

    In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Elbasvir

  • Experimental
    A2: GT1 NC GZR+UPR+RZR (8 weeks)

    In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir

  • Experimental
    A3: GT2 NC GZR+UPR+EBR (8 weeks)

    In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + EBR 50 mg q.d. by mouth for 8 weeks.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Elbasvir

  • Experimental
    A4: GT2 NC GZR+UPR+RZR (8 weeks)

    In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 300 mg + RZR 60 mg q.d. by mouth for 8 weeks.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir

  • Experimental
    A5: GT1 NC GZR+UPR+EBR (8 weeks)

    In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Elbasvir

  • Experimental
    A6: GT1 NC GZR+UPR+RZR (8 weeks)

    In Part A, HCV GT1-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir

  • Experimental
    B7: GT2 NC GZR+UPR+EBR (8 weeks)

    In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + EBR 50 mg q.d. by mouth for 8 weeks.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Elbasvir

  • Experimental
    A8: GT2 NC GZR+UPR+RZR (8 weeks)

    In Part A, HCV GT2-infected NC participants will take GZR 100 mg + UPR 450 mg + RZR 60 mg q.d. by mouth for 8 weeks. In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir

  • Experimental
    B9: GT1 NC GZR+UPR+RZR (12 weeks)

    In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir

  • Experimental
    B10: GT2 NC GZR+UPR+RZR (8 weeks) + RBV

    In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir · Drug: Ribavirin

  • Experimental
    B11: GT2 NC GZR+UPR+RZR (12 weeks)

    In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir

  • Experimental
    B12: GT1 C GZR+UPR+RZR (8 weeks)

    In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir

  • Experimental
    B13: GT1 C GZR+UPR+RZR (12 weeks)

    In Part B, HCV GT1-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir

  • Experimental
    B14: GT2 C GZR+UPR+RZR (12 weeks)

    In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir

  • Experimental
    B15: GT2 C GZR+UPR+RZR (12 weeks) + RBV

    In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 12 weeks. Participants will also take RBV b.i.d. at a total daily dose of 800-1600 mg based on body weight.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir · Drug: Ribavirin

  • Experimental
    B16: GT2 C GZR+UPR+RZR (16 weeks)

    In Part B, HCV GT2-infected C participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 16 weeks.

    Drug: Grazoprevir · Drug: Uprifosbuvir · Drug: Ruzasvir · Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir

  • Experimental
    B6: GT1 NC GZR+UPR+RZR (8 weeks)

    In Part B, HCV GT1-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.

    Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir

  • Experimental
    B8: GT2 NC GZR+UPR+RZR (8 weeks)

    In Part B, HCV GT2-infected NC participants will take 2 FDC tablets containing UPR 225 mg + GZR 50 mg + RZR 30 mg per tablet q.d. by mouth for 8 weeks.

    Drug: Uprifosbuvir (+) Grazoprevir (+) Ruzasvir

Interventions

  • One GZR 100 mg tablet (Part A), or 2 FDC tablets containing GZR 50 mg per tablet (Part B), taken q.d.by mouth.

    Also known as: MK-5172

  • Two or 3 UPR 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or 2 FDC tablets containing UPR 225 mg (Part B), taken q.d. by mouth.

    Also known as: MK-3682

  • One EBR 50 mg tablet (Part A), taken q.d. by mouth.

    Also known as: MK-8742

  • Six RZR 10 mg (60 mg total daily dose) capsules (Part A), or 2 FDC tablets containing RZR 30 mg per tablet (Part B), taken q.d. by mouth.

    Also known as: MK-8408

  • DrugUprifosbuvir (+) Grazoprevir (+) Ruzasvir

    Drug page: MK-3682B

    Two FDC tablets, each containing GZR 50 mg + UPR 225 mg + RZR 30 mg (Part B), taken q.d. by mouth.

    Also known as: MK-3682B

  • RBV 200 mg capsules taken b.i.d. at a total daily dose of 800-1400 mg based on participant body weight.

    Also known as: Rebetol®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Treatment (SVR12)

    The percentage of participants with Hepatitis C virus (HCV) ribonucleic acid (RNA) \< Lower Limit of Quantification (LLoQ) 12 weeks after completing treatment (i.e., SVR12) in each arm was determined. Plasma levels of HCV RNA levels were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 assay, which has a LLoQ of 15 IU/mL.

    Time frame: Up to 28 weeks

  2. Percentage of Participants Experiencing an Adverse Event (AE)

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to 18 weeks

  3. Percentage of Participants Discontinuing From Study Treatment Due to an AE

    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to 16 weeks

Secondary outcomes

  1. Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Ending Study Treatment (SVR24)

    The percentage of participants with HCV RNA \< LLoQ 24 weeks after completing treatment (i.e., SVR24) in each arm was determined. Plasma levels of HCV RNA levels were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 assay, which has a LLoQ of 15 IU/mL.

    Time frame: Up to 40 weeks

07

Results

Posted Dec 21, 2017

Participant flow

This trial was conducted at 95 study sites in Asia, the European Union, and North America.

Participant flow — Overall Study
MilestoneA1: GT1 NC GZR+UPR+EBR (8 Weeks)A2: GT1 NC GZR+UPR+RZR (8 Weeks)A3: GT2 NC GZR+UPR+EBR (8 Weeks)A4: GT2 NC GZR+UPR+RZR (8 Weeks)A5: GT1 NC GZR+UPR+EBR (8 Weeks)A6: GT1 NC GZR+UPR+RZR (8 Weeks)A7: GT2 NC GZR+UPR+EBR (8 Weeks)A8: GT2 NC GZR+UPR+RZR (8 Weeks)B9: GT1 NC GZR+UPR+RZR (12 Weeks)B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBVB11: GT2 NC GZR+UPR+RZR (12 Weeks)B12: GT1 C GZR+UPR+RZR (8 Weeks)B13: GT1 C GZR+UPR+RZR (12 Weeks)B14: GT2 C GZR+UPR+RZR (12 Weeks)B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBVB16: GT2 C GZR+UPR+RZR (16 Weeks)B6: GT1 NC GZR+UPR+RZR (8 Weeks)B8: GT2 NC GZR+UPR+RZR (8 Weeks)
Started232416142323151648313135401516263016
Completed232415132322151648282935351516263016
Not completed001101000320500000
Withdrew: Adverse event000000000000100000
Withdrew: Lost to follow-up000001000020300000
Withdrew: Physician decision000100000000100000
Withdrew: Withdrawal by subject001000000300000000

Outcome measures

PrimaryPercentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Treatment (SVR12)

The percentage of participants with Hepatitis C virus (HCV) ribonucleic acid (RNA) \< Lower Limit of Quantification (LLoQ) 12 weeks after completing treatment (i.e., SVR12) in each arm was determined. Plasma levels of HCV RNA levels were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 assay, which has a LLoQ of 15 IU/mL.

Time frame:
Up to 28 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Treatment (SVR12)
Percentage of ParticipantsA1: GT1 NC GZR+UPR+EBR (8 Weeks)A2: GT1 NC GZR+UPR+RZR (8 Weeks)A3: GT2 NC GZR+UPR+EBR (8 Weeks)A4: GT2 NC GZR+UPR+RZR (8 Weeks)A5: GT1 NC GZR+UPR+EBR (8 Weeks)A6: GT1 NC GZR+UPR+RZR (8 Weeks)B6: GT1 NC GZR+UPR+RVR (8 Weeks)A7: GT2 NC GZR+UPR+EBR (8 Weeks)A8: GT2 NC GZR+UPR+RZR (8 Weeks)B8: GT2 NC GZR+UPR+RZR (8 Weeks)B9: GT1 NC GZR+UPR+RZR (12 Weeks)B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBVB11: GT2 NC GZR+UPR+RZR (12 Weeks)B12: GT1 C GZR+UPR+RZR (8 Weeks)B13: GT1 C GZR+UPR+RZR (12 Weeks)B14: GT2 C GZR+UPR+RZR (12 Weeks)B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBV16: GT2 C GZR+UPR+RZR (16 Weeks)
Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Treatment (SVR12)100.0 (85.2 to 100.0)100.0 (85.8 to 100.0)68.8 (41.3 to 89.0)71.4 (41.9 to 91.6)100.0 (85.2 to 100.0)91.3 (72.0 to 98.9)100.0 (88.4 to 100.0)60.0 (32.3 to 83.7)93.8 (69.8 to 99.8)87.5 (61.7 to 98.4)100.0 (92.6 to 100.0)83.3 (65.3 to 94.4)100.0 (88.4 to 100.0)97.1 (85.1 to 99.9)100.0 (91.0 to 100.0)100.0 (78.2 to 100.0)100.0 (79.4 to 100.0)100.0 (86.3 to 100.0)
PrimaryPercentage of Participants Experiencing an Adverse Event (AE)

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to 18 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Experiencing an Adverse Event (AE)
Percentage of ParticipantsA1: GT1 NC GZR+UPR+EBR (8 Weeks)A2: GT1 NC GZR+UPR+RZR (8 Weeks)A3: GT2 NC GZR+UPR+EBR (8 Weeks)A4: GT2 NC GZR+UPR+RZR (8 Weeks)A5: GT1 NC GZR+UPR+EBR (8 Weeks)A6: GT1 NC GZR+UPR+RZR (8 Weeks)B6: GT1 NC GZR+UPR+RVR (8 Weeks)A7: GT2 NC GZR+UPR+EBR (8 Weeks)A8: GT2 NC GZR+UPR+RZR (8 Weeks)B8: GT2 NC GZR+UPR+RZR (8 Weeks)B9: GT1 NC GZR+UPR+RZR (12 Weeks)B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBVB11: GT2 NC GZR+UPR+RZR (12 Weeks)B12: GT1 C GZR+UPR+RZR (8 Weeks)B13: GT1 C GZR+UPR+RZR (12 Weeks)B14: GT2 C GZR+UPR+RZR (12 Weeks)B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBV16: GT2 C GZR+UPR+RZR (16 Weeks)
Percentage of Participants Experiencing an Adverse Event (AE)60.983.356.371.473.960.962.386.775.068.872.980.671.057.172.553.381.369.2
SecondaryPercentage of Participants Achieving Sustained Virologic Response 24 Weeks After Ending Study Treatment (SVR24)

The percentage of participants with HCV RNA \< LLoQ 24 weeks after completing treatment (i.e., SVR24) in each arm was determined. Plasma levels of HCV RNA levels were measured using the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test, v2.0 assay, which has a LLoQ of 15 IU/mL.

Time frame:
Up to 40 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Ending Study Treatment (SVR24)
Percentage of ParticipantsA1: GT1 NC GZR+UPR+EBR (8 Weeks)A2: GT1 NC GZR+UPR+RZR (8 Weeks)A3: GT2 NC GZR+UPR+EBR (8 Weeks)A4: GT2 NC GZR+UPR+RZR (8 Weeks)A5: GT1 NC GZR+UPR+EBR (8 Weeks)A6: GT1 NC GZR+UPR+RZR (8 Weeks)B6: GT1 NC GZR+UPR+RVR (8 Weeks)A7: GT2 NC GZR+UPR+EBR (8 Weeks)A8: GT2 NC GZR+UPR+RZR (8 Weeks)B8: GT2 NC GZR+UPR+RZR (8 Weeks)B9: GT1 NC GZR+UPR+RZR (12 Weeks)B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBVB11: GT2 NC GZR+UPR+RZR (12 Weeks)B12: GT1 C GZR+UPR+RZR (8 Weeks)B13: GT1 C GZR+UPR+RZR (12 Weeks)B14: GT2 C GZR+UPR+RZR (12 Weeks)B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBV16: GT2 C GZR+UPR+RZR (16 Weeks)
Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Ending Study Treatment (SVR24)100.0 (85.2 to 100.0)100.0 (85.8 to 100.0)68.8 (41.3 to 89.0)71.4 (41.9 to 91.6)100.0 (85.2 to 100.0)90.9 (70.8 to 98.9)100.0 (88.4 to 100.0)60.0 (32.3 to 83.7)93.8 (69.8 to 99.8)87.5 (61.7 to 98.4)100.0 (92.6 to 100.0)83.3 (65.3 to 94.4)100.0 (88.1 to 100.0)97.1 (85.1 to 99.9)100.0 (90.1 to 100.0)100.0 (78.2 to 100.0)100.0 (79.4 to 100.0)100.0 (86.3 to 100.0)
PrimaryPercentage of Participants Discontinuing From Study Treatment Due to an AE

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
Up to 16 weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Discontinuing From Study Treatment Due to an AE
Percentage of ParticipantsA1: GT1 NC GZR+UPR+EBR (8 Weeks)A2: GT1 NC GZR+UPR+RZR (8 Weeks)A3: GT2 NC GZR+UPR+EBR (8 Weeks)A4: GT2 NC GZR+UPR+RZR (8 Weeks)A5: GT1 NC GZR+UPR+EBR (8 Weeks)A6: GT1 NC GZR+UPR+RZR (8 Weeks)B6: GT1 NC GZR+UPR+RVR (8 Weeks)A7: GT2 NC GZR+UPR+EBR (8 Weeks)A8: GT2 NC GZR+UPR+RZR (8 Weeks)B8: GT2 NC GZR+UPR+RZR (8 Weeks)B9: GT1 NC GZR+UPR+RZR (12 Weeks)B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBVB11: GT2 NC GZR+UPR+RZR (12 Weeks)B12: GT1 C GZR+UPR+RZR (8 Weeks)B13: GT1 C GZR+UPR+RZR (12 Weeks)B14: GT2 C GZR+UPR+RZR (12 Weeks)B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBV16: GT2 C GZR+UPR+RZR (16 Weeks)
Percentage of Participants Discontinuing From Study Treatment Due to an AE000000000006.5002.5012.50

Adverse events

Collected over Up to 18 weeks (14 days after completing treatment). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A1: GT1 NC GZR+UPR+EBR (8 Weeks)—0/23 (0%)13/23 (56.5%)
A2: GT1 NC GZR+UPR+RZR (8 Weeks)—1/24 (4.2%)19/24 (79.2%)
A3: GT2 NC GZR+UPR+EBR (8 Weeks)—1/16 (6.3%)10/16 (62.5%)
A4: GT2 NC GZR+UPR+RZR (8 Weeks)—1/14 (7.1%)10/14 (71.4%)
A5: GT1 NC GZR+UPR+EBR (8 Weeks)—0/23 (0%)15/23 (65.2%)
A6: GT1 NC GZR+UPR+RZR (8 Weeks)—0/23 (0%)13/23 (56.5%)
A7: GT2 NC GZR+UPR+EBR (8 Weeks)—0/15 (0%)13/15 (86.7%)
A8: GT2 NC GZR+UPR+RZR (8 Weeks)—0/16 (0%)12/16 (75%)
B6: GT1 NC GZR+UPR+RVR (8 Weeks)—0/30 (0%)18/30 (60%)
B8: GT2 NC GZR+UPR+RZR (8 Weeks)—1/16 (6.3%)11/16 (68.8%)
B9: GT1 NC GZR+UPR+RZR (12 Weeks)—0/48 (0%)35/48 (72.9%)
B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBVMax 62 Characters...—2/31 (6.5%)24/31 (77.4%)
B11: GT2 NC GZR+UPR+RZR (12 Weeks)—0/31 (0%)19/31 (61.3%)
B12: GT1 C GZR+UPR+RZR (8 Weeks)—1/35 (2.9%)19/35 (54.3%)
B13: GT1 C GZR+UPR+RZR (12 Weeks)—3/40 (7.5%)26/40 (65%)
B14: GT2 C GZR+UPR+RZR (12 Weeks)—0/15 (0%)8/15 (53.3%)
B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBV—0/16 (0%)13/16 (81.3%)
B16: GT2 C GZR+UPR+RZR (16 Weeks)—2/26 (7.7%)14/26 (53.8%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventA1: GT1 NC GZR+UPR+EBR (8 Weeks)A2: GT1 NC GZR+UPR+RZR (8 Weeks)A3: GT2 NC GZR+UPR+EBR (8 Weeks)A4: GT2 NC GZR+UPR+RZR (8 Weeks)A5: GT1 NC GZR+UPR+EBR (8 Weeks)A6: GT1 NC GZR+UPR+RZR (8 Weeks)A7: GT2 NC GZR+UPR+EBR (8 Weeks)A8: GT2 NC GZR+UPR+RZR (8 Weeks)B6: GT1 NC GZR+UPR+RVR (8 Weeks)B8: GT2 NC GZR+UPR+RZR (8 Weeks)B9: GT1 NC GZR+UPR+RZR (12 Weeks)B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBVMax 62 Characters...B11: GT2 NC GZR+UPR+RZR (12 Weeks)B12: GT1 C GZR+UPR+RZR (8 Weeks)B13: GT1 C GZR+UPR+RZR (12 Weeks)B14: GT2 C GZR+UPR+RZR (12 Weeks)B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBVB16: GT2 C GZR+UPR+RZR (16 Weeks)
Substance-induced psychotic disorderPsychiatric disorders0/230/240/161/140/230/230/150/160/300/160/480/310/310/350/400/150/160/26
TachycardiaCardiac disorders0/230/241/160/140/230/230/150/160/300/160/480/310/310/350/400/150/160/26
VomitingGastrointestinal disorders0/230/241/160/140/230/230/150/160/300/160/480/310/310/350/400/150/160/26
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/230/240/160/140/230/230/150/160/301/160/480/310/310/350/400/150/160/26
Retinal artery occlusionEye disorders0/231/240/160/140/230/230/150/160/300/160/480/310/310/350/400/150/160/26
Duodenal ulcer haemorrhageGastrointestinal disorders0/230/240/160/140/230/230/150/160/300/160/480/310/310/350/400/150/161/26
PneumoniaInfections and infestations0/230/240/160/140/230/230/150/160/300/160/480/310/310/350/400/150/161/26
OesophagitisGastrointestinal disorders0/230/240/160/140/230/230/150/160/300/160/481/310/310/350/400/150/160/26
DepressionPsychiatric disorders0/230/240/160/140/230/230/150/160/300/160/481/310/310/350/400/150/160/26
Pilonidal cystInfections and infestations0/230/240/160/140/230/230/150/160/300/160/480/310/311/350/400/150/160/26
Most frequent other events
Showing 10 of 127
Most frequent other events
EventA1: GT1 NC GZR+UPR+EBR (8 Weeks)A2: GT1 NC GZR+UPR+RZR (8 Weeks)A3: GT2 NC GZR+UPR+EBR (8 Weeks)A4: GT2 NC GZR+UPR+RZR (8 Weeks)A5: GT1 NC GZR+UPR+EBR (8 Weeks)A6: GT1 NC GZR+UPR+RZR (8 Weeks)A7: GT2 NC GZR+UPR+EBR (8 Weeks)A8: GT2 NC GZR+UPR+RZR (8 Weeks)B6: GT1 NC GZR+UPR+RVR (8 Weeks)B8: GT2 NC GZR+UPR+RZR (8 Weeks)B9: GT1 NC GZR+UPR+RZR (12 Weeks)B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBVMax 62 Characters...B11: GT2 NC GZR+UPR+RZR (12 Weeks)B12: GT1 C GZR+UPR+RZR (8 Weeks)B13: GT1 C GZR+UPR+RZR (12 Weeks)B14: GT2 C GZR+UPR+RZR (12 Weeks)B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBVB16: GT2 C GZR+UPR+RZR (16 Weeks)
HeadacheNervous system disorders3/237/243/162/148/233/235/159/162/303/1615/488/317/315/355/402/152/164/26
NauseaGastrointestinal disorders2/233/241/162/143/230/236/153/165/302/167/485/311/311/353/402/153/164/26
FatigueGeneral disorders4/233/242/162/146/234/236/156/164/303/168/484/311/313/353/401/155/163/26
DizzinessNervous system disorders1/230/240/160/144/230/234/150/161/300/161/480/310/311/351/400/151/160/26
DyspepsiaGastrointestinal disorders0/230/240/160/140/230/233/150/160/301/160/480/311/310/351/400/151/160/26
FlatulenceGastrointestinal disorders1/232/241/160/142/231/233/152/160/300/163/480/312/311/351/400/150/162/26
NasopharyngitisInfections and infestations0/231/241/160/140/230/233/153/160/301/161/483/311/311/353/400/150/161/26
MyalgiaMusculoskeletal and connective tissue disorders0/231/240/160/140/230/233/150/160/300/162/481/312/311/352/400/150/160/26
PruritusSkin and subcutaneous tissue disorders0/231/241/160/140/232/233/150/160/300/161/485/311/310/351/400/151/160/26
VomitingGastrointestinal disorders0/230/240/160/140/230/230/150/162/300/162/481/310/310/351/400/153/162/26

Baseline characteristics

The Baseline Population consists of all randomized participants who received study medication.

Age, Continuous
Age, Continuous(Years)A1: GT1 NC GZR+UPR+EBR (8 Weeks)A2: GT1 NC GZR+UPR+RZR (8 Weeks)A3: GT2 NC GZR+UPR+EBR (8 Weeks)A4: GT2 NC GZR+UPR+RZR (8 Weeks)A5: GT1 NC GZR+UPR+EBR (8 Weeks)A6: GT1 NC GZR+UPR+RZR (8 Weeks)A7: GT2 NC GZR+UPR+EBR (8 Weeks)A8: GT2 NC GZR+UPR+RZR (8 Weeks)B9: GT1 NC GZR+UPR+RZR (12 Weeks)B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBVB11: GT2 NC GZR+UPR+RZR (12 Weeks)B12: GT1 C GZR+UPR+RZR (8 Weeks)B13: GT1 C GZR+UPR+RZR (12 Weeks)B14: GT2 C GZR+UPR+RZR (12 Weeks)B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBVB16: GT2 C GZR+UPR+RZR (16 Weeks)B6: GT1 NC GZR+UPR+RVR (8 Weeks)B8: GT2 NC GZR+UPR+RZR (8 Weeks)Total
Mean50.2 ± 13.545.0 ± 14.549.4 ± 15.852.6 ± 11.649.0 ± 11.246.7 ± 13.952.9 ± 12.148.3 ± 8.848.8 ± 13.949.8 ± 13.055.6 ± 14.458.8 ± 9.656.9 ± 11.161.8 ± 6.859.8 ± 8.064.0 ± 9.347.4 ± 11.751.4 ± 10.852.6 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)A1: GT1 NC GZR+UPR+EBR (8 Weeks)A2: GT1 NC GZR+UPR+RZR (8 Weeks)A3: GT2 NC GZR+UPR+EBR (8 Weeks)A4: GT2 NC GZR+UPR+RZR (8 Weeks)A5: GT1 NC GZR+UPR+EBR (8 Weeks)A6: GT1 NC GZR+UPR+RZR (8 Weeks)A7: GT2 NC GZR+UPR+EBR (8 Weeks)A8: GT2 NC GZR+UPR+RZR (8 Weeks)B9: GT1 NC GZR+UPR+RZR (12 Weeks)B10: GT2 NC GZR+UPR+RZR (8 Weeks) + RBVB11: GT2 NC GZR+UPR+RZR (12 Weeks)B12: GT1 C GZR+UPR+RZR (8 Weeks)B13: GT1 C GZR+UPR+RZR (12 Weeks)B14: GT2 C GZR+UPR+RZR (12 Weeks)B15: GT2 C GZR+UPR+RZR (12 Weeks) + RBVB16: GT2 C GZR+UPR+RZR (16 Weeks)B6: GT1 NC GZR+UPR+RVR (8 Weeks)B8: GT2 NC GZR+UPR+RZR (8 Weeks)Total
Female101375149982116161411349149192
Male131199914682715152129121217167250
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Lawitz E, Buti M, Vierling JM, Almasio PL, Bruno S, Ruane PJ, Hassanein TI, Muellhaupt B, Pearlman B, Jancoriene L, Gao W, Huang HC, Shepherd A, Tannenbaum B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Yoshida EM. Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):814-823. doi: 10.1016/S2468-1253(17)30163-2. Epub 2017 Aug 10. PubMed 28802814 ↗
  • Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben-Ari Z, Foster GR, Agarwal K, Laursen AL, Gerstoft J, Gao W, Huang HC, Fitzgerald B, Fernsler D, Li JJ, Grandhi A, Liu H, Su FH, Wan S, Zeng Z, Chen HL, Dutko FJ, Nguyen BT, Wahl J, Robertson MN, Barr E, Yeh WW, Plank RM, Butterton JR, Esteban R. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):805-813. doi: 10.1016/S2468-1253(17)30159-0. Epub 2017 Aug 10. PubMed 28802816 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Sep 2016, 19 months.

Results were first posted in Dec 2017, 1 year 3 months after primary completion.

Of 48 industry-sponsored phase 2 interventional studies under Hepatitis C, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 26. This study's 19 months is above that.

Counting every sponsor, half of 61 studies reached it within 19 months; a quarter within 13 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2015
First posted
Jan 7, 2015
StartActual
Jan 22, 2015
Primary completionActual
Sep 16, 2016
CompletionActual
Dec 6, 2016
Results first posted
Dec 21, 2017
Last update
Jul 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02332707
Responsible party
Sponsor
First posted
Jan 7, 2015
Start date
Jan 22, 2015
Primary completion
Sep 16, 2016
Completion
Dec 6, 2016
Results posted
Dec 21, 2017
Last update
Jul 23, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Grazoprevir · Uprifosbuvir · Elbasvir · Ruzasvir · MK-3682B

Start the discussion